HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Tolerability and efficacy of switching from oral selegiline to Zydis selegiline in patients with Parkinson's disease.

Abstract
Selegiline is a monoamine-B specific inhibitor used to treat Parkinson's disease. A Zydis sublingual preparation has more efficient absorption and less first pass amphetamine metabolites. We conducted an open label oral to Zydis switch study to evaluate tolerability of rapid switch, and relative efficacy, in 48 subjects from 5 sites. Overall patients preferred the Zydis preparation. Per clinician global impressions, fluctuations improved and the "on" UPDRS part II scores improved. Total UPDRS and measures of fatigue and sleep were unchanged. Adverse events were mild. Patients generally preferred the Zydis selegiline preparation but the modest difference is of unclear clinical significance given the open label nature of the trial.
AuthorsWilliam G Ondo, Christine Hunter, Stuart H Isaacson, Dee E Silver, R Malcolm Stewart, James W Tetrud, Anthony Davidson
JournalParkinsonism & related disorders (Parkinsonism Relat Disord) Vol. 17 Issue 2 Pg. 117-8 (Feb 2011) ISSN: 1873-5126 [Electronic] England
PMID21084213 (Publication Type: Clinical Trial, Comparative Study, Journal Article, Multicenter Study)
CopyrightCopyright © 2010 Elsevier Ltd. All rights reserved.
Chemical References
  • Selegiline
Topics
  • Administration, Oral
  • Administration, Sublingual
  • Aged
  • Chemistry, Pharmaceutical
  • Drug Substitution (methods)
  • Female
  • Follow-Up Studies
  • Humans
  • Male
  • Parkinson Disease (drug therapy, metabolism)
  • Selegiline (administration & dosage, adverse effects)
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password: